• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Valerion develops antibody delivery method for Pompe disease therapy

March 3, 2017 By Sarah Faulkner

Valerion develops antibody delivery method for Pompe disease therapyValerion Therapeutics said today that the company developed a fusion protein, VAL-1221, that combines its antibody delivery system with recombinant human acid alpha-glucosidase (rhGAA) to better deliver rhGAA into affected tissues of patients with Pompe disease.

Patients who suffer from Pompe disease have a deficient supply of the lysosomal enzyme, GAA, which causes glycogen to accumulate in cardiac and skeletal muscles. Although researchers have observed that glycogen accumulates in both lysosomes and cytoplasm of Pompe disease patients, the currently-approved enzyme-replacement therapy only clears glycogen in the lysosome.

Researchers at Duke University demonstrated that Valerion’s antibody-mediated enzyme-replacement therapy is effective in cultured Pompe patient fibroblasts and in Pompe GAA-deficient mice.

VAL-1221 cleared away lysosomal glycogen as effectively as current enzyme-replacement therapy, according to the study results, and also penetrated living cells independent of the cell entry mechanism associated with current treatment methods. The team of researchers suggested that VAL-1221’s delivery mechanism could be better than traditional therapies because it clears both lysosomal and cytoplasmic glycogen.

“We believe our findings are a game-changer in the treatment of Pompe disease,” CEO Deborah Ramsdell said in prepared remarks. “We are excited about the potential to help patients who are looking for alternatives to the current approved therapy.”

The Concord, Mass.-based company plans to initiate a clinical trial in the U.S. and the UK next month to evaluate its VAL-1221 therapy in patients with late-onset Pompe disease.

The randomized, dose-escalation trial will study the treatment’s safety, tolerability and preliminary efficacy in ambulatory and ventilator-free patients. Valerion said it expects top line results later this year.

“The approach is different from other ERT approaches as this has the ability to act on glycogen in the cytoplasm. This remains a challenge in the field of Pompe disease,” principal investigator Dr. Priya Kishnani added. “Glycogen that is leached out (either due to shearing effect or rupture of lysosomes) into cytoplasm needs to be cleared.  The collaboration with Valerion is an important one as it allows us to look at whether VAL-1221 has this additional benefit.”

Filed Under: Drug-Device Combinations, Featured, Research & Development Tagged With: Duke University, Valerion Therapeutics

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS